Graduation date: 1991

Previous studies have found that smoking may have a negative effect on vitamin B-6 indices and have demonstrated a possible association between smoking and depressed plasma pyridoxal-5'-phosphate (PLP) concentration. Individuals with plasma PLP values below the adequate level of 30 nmoles/L might benefit from consumption of vitamin B-6 supplements, but no data are available on vitamin B-6 status in smokers consuming a controlled vitamin B-6 intake and receiving a vitamin B-6 supplement. The objectives of this research were to assess vitamin B-6 status in smokers as compared to non-smokers receiving a controlled diet and to evaluate the effect of an oral vitamin B-6 supplementation in these subjects. The vitamin B-6 (B-6) status of 5 (four males / one female) smokers (S) and 4 (three males / one female) non-smokers (NS) was assessed. A constant diet was fed for 20 days and provided 1.95 mg of B-6 or 1.65 mg of B-6 for males and females, respectively. For the last 10 days, an additional 2-mg of pyridoxine (PN) was given daily. Blood samples were collected on days 1.7, 11.14 and 21; and 24 hour urine samples were collected daily. Urinary 4-pyridoxic acid (4-PA) and total B-6 (UB6) excretion, plasma B-6 vitamers (PLP, PN, pyridoxal and 4-PA) and red blood cell PLP (RBC PLP) concentrations, as well as plasma alkaline phosphatase activity (APA) were determined. Mean plasma PLP, 4-PA, and RBC PLP concentrations were significantly lower (P [less than or equal to] 0.05) at all time points in S compared to NS. With a daily supplement of 2-mg vitamin B-6, the mean plasma PLP concentration of S increased 85.8% but was 48.5% lower than that of NS consuming 1.65-1.95 mg/d of B-6. Mean plasma pyridoxal concentrations were not different between S and NS before and after supplementation. Excretion of 4-PA was not significantly different between S and NS, but the mean values of 4-PA excretion were consistently greater in NS compared to that of S throughout the 20-day study. The percent of ingested B-6 excreted as 4-PA for the S and NS was 38 and 49 in the non-supplemented period, and 47 and 53 in the supplemented period, respectively, indicating that non-smokers excreted more 4-PA than smokers. However, the difference in 4-PA excretion between S and NS was not significantly different both before and after supplementation (P>0.05). In addition, there was no significant difference between S and NS for plasma PN concentration, AP, and UB6 excretion for both periods. Results suggested an adverse effect of smoking on B-6 metabolism, thus an increased requirement of vitamin B-6 in smokers. A 2-mg PN supplement was sufficient to bring the concentration of plasma PLP in smokers to the level suggested as adequate, but it didn't bring it to the level of non-smokers. / Graduation date: 1999

Graduation date: 1994

Two studies were conducted to determine the effect of varying vitamin B-6 (B- 6) status on lymphocyte mitogenic response and pyridoxal 5'-phosphate (PLP) concentration in peripheral blood mononuclear cells (PBMC) in young women. In the first study, women were fed 1 mg/d for the first week and 1.5, 2.1 and 2.7 mg/d during 2 weeks of each of the subsequent 3 experimental periods. Plasma PLP and urinary 4: pyridoxic acid (4-PA) were increased with increasing B-6 intake. B-6 intake > 2.1 mg significantly enhanced lymphocyte proliferation, and non-significantly increased plasma interleukin-2 concentration. Lymphocyte proliferation was significantly correlated with B-6 intake, erythrocyte aminotransferase activity coefficients and plasma PLP. PBMC PLP tended to increase after 2 weeks of 2.7 mg B-6 intake, and was significantly correlated with plasma PLP. In the second study, women consumed their normal diets whose estimated mean dietary B-6 intake was 0.9 mg for 27 d. For the last 20 d, all subjects were given a multivitamin supplement containing 1.8 mg B- 6, and half of the subjects were given an additional 50 mg of B-6 supplement. Plasma PLP and urinary 4-PA were significantly higher in the group with 50 mg B-6, but lymphocyte proliferation did not significantly differ between the groups. After 10 d of supplementation, lymphocyte proliferation was significantly higher than the other time points. A significant increase in PBMC PLP was observed after 3 days and 20 days following 50 mg and multivitamin supplementation only, respectively. After 20 days of supplementation, there was no significant difference of mean PBMC PLP between the groups. PBMC PLP was significantly correlated with plasma PLP, PL and 4-PA. In both studies, no strong relationship was found between PBMC PLP and lymphocyte proliferation. The findings from these studies demonstrate no further benefit of a higher B-6 intake than 2.1 mg on lymphocyte mitogenic response, once the response was significantly enhanced with B-6 intake 0.8 mg higher than the current recommendation. Finally, results from two studies suggest that the current recommendation of vitamin B-6 for young women may not be adequate to maximize lymphocyte mitogenic response and PLP concentration in PBMC. / Graduation date: 2002

This study examined the effect of vitamin B-6 supplementation and exhaustive submaximal exercise on plasma catecholamine concentrations, and the relationship between plasma catecholamines and fuel use, heart rate and oxygen consumption. Five trained men (age= 18-35 years; V0₂max=53 ml 0₂/kg/min.) participated in two controlled dietary periods that were identical except for the addition of 20 mg/d pyridoxine (PN) supplementation during the second period. On the seventh morning of each period, fasted subjects exercised to exhaustion on a cycle ergometer at 74.5% ± 7.8 V0₂max. Blood was drawn pre-exercise (twice), 60 minutes into exercise, immediately post-exercise and 60 minutes post-exercise. Plasma was analyzed for norepinephrine, epinephrine, glucose, pyridoxal 5'-phosphate (PLP), lactic acid, glycerol and free fatty acids (FFA). Heart rate and oxygen consumption were measured pre-exercise and at 10-minute intervals during exercise. Mean plasma PLP concentration was significantly higher during the supplemented versus the nonsupplemented trial at all time points. There were no statistically significant differences in mean plasma catecholamine concentrations or mean plasma fuel concentrations between the nonsupplemented and supplemented trials at any of the time points examined. There were significant changes in the mean plasma concentrations of norepinephrine, lactic acid, glycerol and FFA over time in both trials. Respiratory exchange ratios (R) were higher during the supplemented trial compared to the nonsupplemented trial, but the differences did not attain statistical significance. There were no significant differences in mean exercise times to exhaustion or mean heart rates between the trials. The overall mean oxygen consumption during exercise was consistently higher during the supplemented versus the nonsupplemented trial and the difference attained significance (p=0.016) at one time point (10 min.). The mean oxygen consumption during rest was lower during supplementation versus nonsupplementation, but the difference was not statistically significant. The percent plasma volume change (PVC) was significantly greater at post-exercise, relative to pre-exercise, during the supplemented versus the nonsupplemented trial. The percent PVC also increased significantly over time during the supplemented but not the nonsupplemented trial. These results suggest that 20 mg/d of vitamin B-6 supplementation does not effect plasma catecholamine concentrations, fuel utilization or heart rate at rest or during submaximal exercise to exhaustion. The results may suggest a higher oxygen consumption during exhaustive exercise after PN supplementation. / Graduation date: 1996